Anacetrapib (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Anacetrapib" in French language version.

refsWebsite

Global rank French rank

3sciencedirect.com

149^th place

80^th place

low place

low place

low place

3,702^nd place

2,374^th place

298^th place

485^th place

416^th place

1oxfordjournals.org

1,389^th place

508^th place

jci.org (Global: low place; French: 3,702^nd place)

Millar JS, Reyes-Soffer G, Jumes P et al. Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects, J Clin Invest. 2015;125:2510-2522.

jlr.org (Global: low place; French: low place)

Krauss RM, Wojnooski K, Orr J et al. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib, J Lipid Res, 2012;53:540-547

nejm.org (Global: 2,374^th place; French: 298^th place)

The HPS3/TIMI55–REVEAL Collaborative Group, Effects of anacetrapib in patients with atherosclerotic vascular disease, N Engl J Med, 2017;377:1217-1227

oup.com (Global: 485^th place; French: 416^th place)

academic.oup.com

Sammons E, Hopewell JC, Chen F et al. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease, Eur Heart J, 2021;43:1416–1424

oxfordjournals.org (Global: 1,389^th place; French: 508^th place)

eurheartj.oxfordjournals.org

Kühnast S, van der Tuin SJ, van der Hoorn JW et al. Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin, Eur Heart J, 2015;36:39-50

sciencedirect.com (Global: 149^th place; French: 80^th place)

Bloomfield D, Carlson GL, Sapre A et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients, Am Heart J, 2009;157:352-360. e2
Krishna R, Anderson MS, Bergman AJ et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies, Lancet, 2007;370:1907-1914
Han S, Levoci L, Fischer P et al. Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein, Biochim Biophys Acta, 2013;1831:825-833